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Abstract: The identification of quantitative trait loci, QTL, in arthritis animal models is a straight forward process. How-
ever, to identify the underlying genes is a great challenge. One strategy frequently used, is to combine QTL analysis with 
genomic/proteomic screens. This has resulted in a number of publications where carefully performed genomic analyses 
present likely candidate genes for their respective QTL´s. However, seldom the findings are reconnected to the QTL con-
trolled phenotypes. In this review, we use our own data as an illustrative example that “very likely candidate genes” iden-
tified by genomic/proteomics is not necessarily the same as true QTL underlying genes. 
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1. INTRODUCTION 
  Despite last decade’s therapeutic progression, Rheuma-
toid arthritis (RA) still lacks cure and satisfactory treatment 
in many cases. To make a change, it is urgent to elucidate the 
underlying disease mechanisms. As RA has a genetic com-
ponent of ~60% [1], one way to go is to identify predispos-
ing genes. The strongest genetic contribution to RA comes 
from the HLA region, which is expected to count for about 
35% of the genetic predisposition [2]. However, to learn 
more about underlying mechanisms also additional contrib-
uting genes need to be identified. Unfortunately, this has 
turned out to be far from easy as the genetics behind RA is 
complex, i.e. heterogeneous, polygenetic with low pene-
trance of each contributing gene, epistatic and with interac-
tion between genes and environment. As the human popula-
tion is outbred and exposed to highly variable environment, 
it is really difficult to reproducibly, identify predisposing 
genes in human material. Also, phenotypes necessary for the 
understanding of disease mechanisms (e.g. disease on-set 
and progression from acute to chronic inflammation) cannot 
be studied in humans as most patients once they get their 
diagnosis already are in a chronic state of disease. In an at-
tempt to overcome these problems, we and others use animal 
models. Animals can be genetically and environmentally 
controlled, genetically manipulated and the disease can be 
followed in detail before on-set until the progression into 
chronic disease.  
2. FIRST STEP OF GENE IDENTIFICATION –QTL 
IDENTIFICATION 
  Firstly, to identify RA relevant genes in rodents, a dis-
ease model with high similarity to the human disease has to 
be chosen. Several such models have been developed; e.g. 
induction by injection of cartilage proteins in adjuvant oils 
[3] or by injection of adjuvant oils only (in rats) [4]. A draw-
back of some models is that they only result in acute self- 
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healing arthritis, but some models e.g. autologous collagen II 
induced arthritis, aCIA, and pristane-induced arthritis, PIA, 
in rats [5] are also suitable for studies on chronic relapsing 
arthritis. In resemblance to RA these models are highly de-
pendent on the genetic background, with MHC as the most 
important individual region, but with obvious contribution 
also of other genes [5, 6]. The assumption is that these other 
genes also need to be identified in order to understand RA. 
To do so, a first step is to identify chromosomal loci control-
ling quantitative arthritic traits (quantitative trait loci, QTL). 
This is done with genome-wide linkage analyses in crosses 
between susceptible and resistant strains. Nowadays, QTL 
identification is pretty strait forward and ~70 joint/bone in-
flammation QTL´s have been identified for the rat [7] and 
almost 400 arthritis QTL´s for the mouse [8]. However, the 
subsequent step, to identify the underlying gene(s), has 
turned out to be challenging. So far, only a small number of 
genes have been identified from a QTL and then it has been 
genes from QTLs that have extraordinary large effect sizes 
[9]. 
3. STRATEGIES FOR GENE CLONING FROM A QTL 
  Before consider strategies for cloning a gene from a 
QTL, one has to be aware of what one is looking for. As has 
been nicely pointed out by Flint et al. [9] most single nucleo-
tide polymorphisms, SNPs, underlying QTL´s for complex 
diseases are not likely to be found within coding-sequences. 
In the worse case the position of the quantitative trait nucleo-
tide, QTN does not coincide with the position of the gene it 
is affecting (trans-regulated genes). However, let us assume 
that the causative variant of a gene indeed is encoded from 
the QTL. Then, to work out strategies for its identification it 
is important to have in mind which criteria such a gene 
should fulfill. Suggested criteria are; the gene should be po-
lymorphic in a way that leads to altered protein product or 
differential expression, its expression should be detected in 
organs or cell types of relevance and the gene shall have a 
function either related to the trait directly or in a biologic 
pathway of relevance for the trait [10, 11]. However, a typi-
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allow criteria fulfillment analysis of all the genes. Therefore, 
the QTL need to be narrowed to reduce the possible candi-
dates to a number that can be handled for investigation. To 
narrow a QTL, one can choose between safe, “hard-core 
evidence” strategies and “likelihood” based strategies. The 
former are often expensive, laborious and time-consuming 
sometimes even beyond the border of be performable at all. 
The second strategy is not so safe but can more easily be 
afforded, economically as well as time- and effort-wise. 
3.1. Safe, “Hard-Core Evidence” Strategies 
  The classical way of gene identification is to construct a 
congenic strain where the QTL region of the F2-cross paren-
tal strains “A” has been substituted with the corresponding 
region from parental strain “B”. This is done by systematic 
breeding for 6-10 generations depending on method [12], to 
receive a” B”- derived QTL genomic fragment on a pure “A” 
background genome. If the phenotype can be reproduced in 
the congenic animal, one can conclude that the affecting 
polymorphism indeed is encoded from this region. To nar-
row the causative fragment using the congenic animals, the 
animals are further backcrossed and genotyped. Off-springs 
where a genomic recombination has occurred, resulting in a 
smaller “B” –derived congenic fragment, are tested for the 
disease phenotype. Congenics positive for the phenotype are 
selected for further backcross. This method is safe when sys-
tematically performed and has successfully been used in 
cloning of the arthritis susceptibility gene Ncf1 [13]. How-
ever, to be feasible, as discussed below, it assumes that the 
QTL underlying gene has a strong, dominant, sex-indepen- 
dent effect on the phenotype. In addition, this strategy is time 
consuming as it is dependent of recombinant events to occur, 
which cannot be forced. The only possibility to speed up the 
procedure is to provide resources for a large breeding and 
simultaneous phenotype-testing of many subcongenics. An-
other strategy to collect recombination is to produce ad-
vanced intercross lines (AIL) [14]. In these lines recombina-
tions are collected by continue the intercross several genera-
tions beyond F2. AIL´s has been successfully used to narrow 
down several QTLs including QTL´s for autoimmune dis-
eases in mice and rat [15-18]. An extension of this strategy is 
the uses of heterogeneous stocks (HS) that are AIL with sev-
eral parental strains [19]. A disadvantage of these strategies 
is that they require time and space for (production)/hosting 
and phenotyping the lines as well as facilities for high-
trough-put genotyping. 
3.2. More Easily Affordable “Likely Hood” Strategies 
  As most of the “safe” hard core evidence strategies have 
large requirements of infra structure and economical re-
sources many scientists turn to more easily performable 
“likely hood”-strategies. Even it may be argued that these 
strategies are more ethically correct as they more quickly can 
provide data for validation in humans and require fewer ex-
periment animals.  
  The cheapest, but often foreseen, method is to use bioin- 
formatics tools to narrow rodent QTL´s [20]. Already a lots 
of data (especially for the mouse) are available in data bases 
all over the world and if correctly analyzed they can save a 
lot of time, money and laboratory efforts. An interesting, 
combined strategy for identifying QTL underlying genes 
with bioinformatics tools have been suggested in [20]. This 
includes comparative genomics, combined cross analysis, 
interval specific haplotype analysis, sequence comparison 
and expression data base analysis. 
  An intermediate strategy effort and economically wise, is 
to make congenes and use genomic and proteomic screens to 
narrow the QTL. This strategy is aimed to, in a nearly unbi-
ased way, find genes within the QTL that fulfills the differ-
ential qualitative protein product and differential expression 
criteria for QTL underlying genes. This strategy have gained 
popularity after some nice publications showing that the 
strategy indeed works and gives candidate genes that can be 
referred back to the QTL phenotype [21-24]. In the light of 
this we also tried this strategy with our QTL Pia6 that spe-
cifically control the chronic phase of PIA. 
4. BACKGROUND OF THE DA.PIA6 CONGENE 
  The PIA6 QTL was identified in an F2-cross between the 
PIA susceptible DA and PIA resistant E3 rat [6]. The region 
was specifically associated with arthritis chronicity increas-
ing in importance over time (no of affected paws day83, 
LOD score 4.2 and day 120, LOD score 4.9). The inheritance 
was DA recessive with E3 as the protective parental. The 
variance explained by the locus was 16-19% and the peak 
marker was D14Csna (21.9 MBp) and flanking markers were 
approximately at 15 MBp and 45 MBp (positions according 
to reference sequence, NCBI). We produced a congenic rat, 
DA.Pia6 with speed congenic technique. A ~50Mp fragment 
between D14Wox8 (19.1 MBp) and D14rat64 (68.6 MBp) 
from the E3 rat was introgressed on a DA background. This 
congenic rat was shown to specifically protect from chronic 
arthritis [25]. Using this rat, the underlying gene should be 
possible to clone and generate essential knowledge of 
chronic inflammation specific processes. 
  Previously, in our lab, it was shown that a gene, Ncf1, 
underlying a QTL Pia4 indeed could be positionally cloned 
using a strategy of recombinant selection where the disease 
phenotype was used as selection criteria [13]. However, sev-
eral important things differ between the Pia4 and Pia6. The 
Pia4 phenotype, which quickly is evaluated, could be seen in 
relatively few heterozygous individuals of both sexes. This 
meant that if a new recombinant rat was a male it could pro-
duce enough of individuals for testing the disease phenotype 
in one generation, =19weeks
1 and then the phenotype would 
take additional 3 weeks to test. In the Pia6 rat, heterozygous 
rats of both sexes most likely are protected, but a strong, 
significant phenotype using a reasonable number of rats can 
only be seen in homozygous, male rats. Practically, this 
means that a new recombinant Pia6 rat would need to be 
bred to produce off-springs: =19weeks, then the off-springs 
need to be intercrossed to produce homozygous rats: = addi-
tional 19 weeks. As only males can be used and in a higher 
number than in the Pia4, eventually one more amplifying 
breeding step has to take place: = additional 19 weeks. Then 
it would be possible to test the new recombination for the  
 
                                                 
1 From the birth of a rat it takes approximately eight weeks until it can be put on breed-
ing, three more weeks until the pups are born and additionally eight weeks until the pup 
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disease phenotype, which for the Pia6 rat takes 12-15 weeks 
to evaluate. Accordingly, the same procedure which took 22 
weeks for the Pia4 rat would take 12-18 months for the Pia6 
rat! Obviously, recombinant selection, using the disease as 
phenotype, was not a plausible strategy to identify the gene 
underlying Pia6. One alternative strategy could be to inves-
tigate immunological subphenotypes of importance for the 
disease phenotype and use them for testing the recombinant 
fragments (subphenotype assisted recombinant selection). 
Another strategy could be to narrow down a fragment sur-
rounding gene/genes with functions likely to be important 
for regulation of (chronic) inflammation (candidate gene 
assisted recombinant selection). However, immunological 
subphenotyping of healthy and arthritic rats in various dis-
ease phases only gave one obscure subphenotype; differen-
tial plasma protein concentration of alpha-1-acid glycopro-
tein and alpha-1-microglobulin [25] and the genetic region 
did not encode any immunological genes of obvious interest. 
Therefore, we turned to the use of genomic and proteomic 
screens to detect candidate genes in the Pia6 region.  
5. EXPRESSION PROFILING STRATEGY TO NAR-
ROW DOWN PIA6 
  Initially we performed an Affymetrix screen of healthy 
and immunized rats from the background strains DA and E3 
and searched for candidates within the Pia6 regions [26]. 
However, the only differentially expressed gene mapping to 
rat chromosome 14 was Bst1 and this was positioned too far 
away from the Pia6 peak to be a reasonable candidate. 
Therefore, we decided to make a new affymetrix screen with 
tissues from the DA.Pia6 rat and DA rat in the late chronic 
phase of PIA, day 127 after immunization (and also healthy 
rats of both strains as control). We choose to analyze spleen, 
lymph nodes and paws and then also liver because of our 
plasma protein phenotype. We analyzed the tissue on U34A 
chips and ended up with ~50 differentially expressed genes 
(Change p-value 0 for increased and 1 for decreased accord-
ing to Affymetrix software) per tissue and time point for the 
liver and lymph nodes, ~half the number in spleen and dou-
ble the number in paws. The resulting list of genes we com-
pared to genes positioned in the interval 19.1-68.9 MBp on 
rat chromosome 14 according to NCBI. 19 of the differen-
tially expressed genes (all tissues) were encoded from the 
fragment (Table 1) and thereby fulfilled one criterion for 
being candidates for the Pia6 underlying genes, differential 
expression. Most of the genes were position between 19-22 
MBp, which correlated well with the original linkage analy-
sis peak D14csna (21.9MBp) a group of three genes were 
positioned around 33-34 Mbp and a third group was posi-
tioned around 45MBp. The linkage analysis peaks gene, ca-
Table 1.  Differentially Expressed Genes in DA and DA.Pia6 Rats Positioned within the DA.Pia6 Congenic Fragment 
Position (MBp)*  Gene 
Liver  
Day 0 
Liver  
Day 127 
LN  
Day 0 
LN  
Day 127 
Spleen  
Day 0 
Spleen  
Day 127 
Paws  
Day 127 
19.1 Alb            
19.3 Rn.8442           
20.5 Slc4a4          
20.9  Rn.165282          
21.1 Ambn         
21.4 Vcsa2          
21.9 Csn1s1          
22.0 Sult1b1           
22.4 Ugt2b4         
22.5 Rn.11131            
22.6 Udpgtr2           
22.8 Yt521          
33.5 Ppat          
33.5 Paics           
34.3  Rn.21892          
34.5** Kdr          
44.1 Uchl1          
45.6 Ugdh          
46.2 Klf3           
*Position according to the reference sequence map at http://www.ncbi.nlm.nih.gov/mapview/ 
**Not positioned in reference sequence, but at 31.5 in the Celera map. 34.5 is estimated according to the position of neighbor genes positioned in both Celera and reference map. Gene Expression Profiling as a Tool for Positional Cloning  Current Genomics, 2008, Vol. 9, No. 7    497 
sein alpha, was differentially expressed. This could be an 
interesting observation as casein expression in lymph nodes 
is correlated to recovery from Experimental autoimmune 
encephalomyelitis, EAE [27]. This is especially interesting 
since the Pia6 also controls the number of relapses in EAE 
[28]. Another interesting candidate in this region was the 
splice factor YT521, which is involved in alternative splicing 
of soluble interleukin 4-receptor [29]. The most promising 
candidate in the 33-34 Mbp region is Kdr as it is essential for 
angiogenesis which plays an important role in arthritis [30]. 
The differentially expressed genes around 45MBp is re-
garded as less likely candidates as they are positioned on the 
QTL flanking border. 
6. PROTEOMIC STRATEGY TO NARROW DOWN 
PIA6 
  QTL underlying genes do not necessarily have to show 
differential expression, but can show qualitative differences 
in the protein product. Such differences might be detectable 
on a 2D gel. Therefore, in parallel with the Affymetrix ex- 
periment, we did 2D gel screens of the DA and DA.pia6 rats. 
As we had a robust, reproducible phenotype in the differen- 
tial concentration of plasma lipocalin proteins, we decided to 
analyze plasma from healthy and chronically ill DA and 
DA.Pia6 rats. After repeating each gel run at least three 
times per animal and time point, we could observe on major 
spot difference between DA and heterozygous DA.Pia6 rats 
both in healthy and chronically ill animals (Fig. 1). The DA 
rat had one spot in this position whereas the DA.Pia6 rat had 
two. After extraction, digestion and mass-spectrometry 
analysis of the resulting peptides we could identify the spots 
as isoforms of vitamin D binding protein most likely repre-
senting different glycoforms. The vitamin D binding protein 
is encoded from the Gc locus positioned at 20.2 MBp, very 
close to the top marker in the linkage analysis (Csna, 21.9). 
Interestingly, vitamin D binding protein plays an important 
role in regulation of neutrophils and activation of macro-
phages [31-33]. Accordingly, both regarding its mapping 
position and its known function it was a very likely candi-
date for the gene underlying the Pia6 QTL. 
7. VALIDATION OF THE STRATEGIES-RESULTS 
FROM SUBCONGENES 
  Subsequently, after our two large screens we had a hand-
ful of really good candidates for the Pia6 QTL underlying 
genes. However, to validate our genomic/proteomic strategy 
we run a PIA experiment with two, still large, subcongenics 
basically dividing our original congene in two overlapping 
parts; a telomeric part (borders 19.1 MBp-33.5 MBp 
(d14rat14)) and a centromeric part (borders 68.9MBp -
32.6MBp (d14rat8)). According to the position of the origi-
nal linkage analysis peak, most genomic candidate genes and 
our proteomic candidate gene, we expected that the telomeric 
fragment would exert the effect. However, to our great sur-
prise we could not detect any arthritis protective effect in the 
telomeric subcongene (Fig. 2A). On the opposite, a protec-
tive effect was found in the centromeric fragment (Fig. 2B). 
Surprised by reality, we were skeptical and repeated the ar-
thritis experiment several times, but the outcome was the 
same: The effect was indeed in the centromeric part. This  
 
excluded the vitamin D binding protein and all genomic can-
didates except, Rn.21892 and Kdr, Ppat and Paics (eventu-
ally as they are positioned on the subcongenic fragment bor-
der) and Uchl1, Ugdh and Klf3 (eventually, positioned too 
far away from the original linkage analysis peak). Though, 
Kdr is a promising candidate gene to investigate further, the 
result highlights the risks of the genomic/proteomic strategy 
in narrowing a QTL. A likely gene is not always the same as 
a true gene and our findings clearly illustrates the necessity 
of reconnecting found candidates to the disease model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). 2D gel analysis of plasma from DA and DA.PIA6 rats. 
Plasma from healthy and chronically ill DA and DA.Pia6 rats were 
separated by charge on pH4-7 Immobiline dry strips and separated 
for size on 12% SDS-PAGE. All samples were repeated three 
times. According to analysis there was one major difference be-
tween the DA and DA.Pia6, the single (DA) and duplicated spot 
(DA.Pia6+/-) (marked with a ring). According to mass-
spectrometry these dots were identified as two isoforms of the vi-
tamin D binding protein encoded from the Gc locus. 
8. CONCLUSIONS AND SUGGESTIONS 
  The joint conclusion from publications in the field and 
our own data is that a genomic/proteomic strategy to narrow 
QTLs can work, but is combined with large risks to get lost. 
In the initial reports of genomics as a tool to narrow QTLs 
and in some later publications, the finding of candidate genes 
is reconnected to the animal models for confirmation. How-
ever, often this is not the case, and in the light of our data, it 
is very risky. If we had not reconnected our findings to our  
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animal model, we would have been convinced that we had 
found the candidates for our QTL. If we then would, in line 
with many publications, have started to investigate our can-
didates in vitro we would certainly have detected functions 
of theoretical importance for arthritis. However, theoretical 
importance is not the same as true importance and we would 
have lost the benefit of letting the disease show us relevant 
genes and biological pathways rather than vice versa. 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). PIA experiment of DA and telomeric and centromeric 
DA.Pia6 subcongenic rats. Pristane was injected in DA, telomeric 
DA.Pia6 and centromeric DA.Pia6 rats and the animals were fol-
lowed for clinical signs of arthritis for 75 days. The telomeric sub-
congenic of DA.Pia6 (A, ) does not have any effect on the arthri-
tis, while the centromeric DA.Pia6 subcongenic (B, ) is protected 
in the chronicle, relapsing phase of arthritis.  
  Therefore, in our opinion genomic/proteomic strategies 
as well as bioinformatics tools should be regarded as ways to 
come up with qualitative hypothesis rather than final proofs. 
Unfortunately, in the end, more laborious strategies like AIL 
or HS might be the shortest way around. If one is short in 
infra structure for this one may try “light version” of these 
strategies, nicely demonstrated to work for CIA by Yu [34] 
and Johannesson [35] or search for helpful collaborators.  
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ABBREVIATIONS 
aCIA  =  Autologus Collagen II Induced Arthritis 
AIL  =  Advanced Intercross Line 
CIA  =  Collagen II Induced Arthritis 
EAE =  Experimental  Autoimmune  Encephalo-myelitis 
HS =  Heterogeneous  Stock 
LOD  =  Logaritm of Odds 
MBp = Mega  Base  pair 
MHC = Major  Histocompatibility  Complex 
NCBI  =  National Center for Biotechnology Information 
PIA  =  Pristane Induced Arthritis 
PIA4  =  Pristane Induced Arthritis quantitative trait locus 4 
PIA6  =  Pristane Induced Arthritis quantitative trait locus 6 
QTL =  Quantitative  Trait  Locus 
QTN = Quantitative  Trait  Nucleotide 
RA =  Rheumatoid  Arthritis 
SNP  =  Single Nucleotide Polymorphism 
REFERENCES 
[1]  MacGregor, A.J., Snieder, H., Rigby, A.S., Koskenvuo, M., 
Kaprio, J., Aho, K., Silman, A.J. Characterizing the quantitative 
genetic contributionto rheumatoid arthritis using data from twins. 
Arthritis Rheum. 2000, 43: 30-7. 
[2]  Deighton, C.M., Walker, D.J., Griffiths, I.D., Roberts, D.F. The 
contribution of HLA to rheumatoid arthritis. Clin. Genet. 1989, 36: 
178-82. 
[3]  Holmdahl, R., Bockermann, R., Bäcklund, J., Yamada, H. The 
molecular pathogenesis of collagen-induced arthritis in mice--a 
model for rheumatoid arthritis. Ageing Res. Rev. 2002, 1: 135-147. 
[4]  Holmdahl, R., Lorentzen, J.C., Lu, S., Olofsson, P., Wester, L., 
Holmberg, J., Pettersson, U. Arthritis induced in rats with non-
immunogenic adjuvants as models for rheumatoid arthritis. Immu-
nol. Rev. 2001, 184:184-202. 
[5]  Vingsbo, C., Sahlstrand, P., Brun, J.G., Jonsson, R., Saxne, T., 
Holmdahl, R. Pristane-induced arthritis in rats: a new model for 
rheumatoid arthritis with a chronic disease course influenced by 
both major histocompatibility complex and non-major histocom-
patibility complex genes. Am. J. Pathol. 1996, 149(5):1675-1683. 
[6]  Vingsbo, C., Jonsson, R., Holmdahl, R. Avridine-induced arthritis 
in rats; a T cell-dependent chronic disease influenced both by MHC Gene Expression Profiling as a Tool for Positional Cloning  Current Genomics, 2008, Vol. 9, No. 7    499 
genes and by non-MHC genes. Clin. Exp. Immunol. 1995, 99 (3): 
359-63. 
[7]  Rat Genome Database [http://rgd.mcw.edu/wg/] 
[8]  Mouse Genome Informatics [http://www.informatics.jax.org/] 
[9]  Flint, J., Valdar, W., Shifman, S., Mott, R. Strategies for mapping 
and cloning quantitative trait genes in rodents. Nat. Rev. Genet. 
2005, 6: 271-286. 
[10]  Abiola, O., Angel, J.M., Avner, P., Bachmanov, A.A., Belknap, 
J.K., Bennett, B., Blankenhorn, E.P., Blizard, D.A., Bolivar, V., 
Brockmann, G.A., Buck, K.J., Bureau, J.F., Casley, W.L., Chesler, 
E.J., Cheverud, J.M., Churchill, G.A., Cook, M., Crabbe, J.C., Cru-
sio, W.E., Darvasi, A., de Haan, G., Dermant, P., Doerge, R.W., 
Elliot, R.W., Farber, C.R., Flaherty, L., Flint, J., Gershenfeld, H., 
Gibson, J.P., Gu, J., Gu, W., Himmelbauer, H., Hitzemann, R., 
Hsu, H.C., Hunter, K., Iraqi, F.F., Jansen, R.C., Johnson, T.E., 
Jones, B.C., Kempermann, G., Lammert, F., Lu, L., Manly, K.F., 
Matthews, D.B., Medrano, J.F., Mehrabian, M., Mittlemann, G., 
Mock, B.A., Mogil, J.S., Montagutelli, X., Morahan, G., Mountz, 
J.D., Nagase, H., Nowakowski, R.S., O'Hara, B.F., Osadchuk, 
A.V., Paigen, B., Palmer, A.A., Peirce, J.L., Pomp, D., Rosemann, 
M., Rosen, G.D., Schalkwyk, L.C., Seltzer, Z., Settle, S., Shimo-
mura, K., Shou, S., Sikela, J.M., Siracusa, L.D., Spearow, J.L., 
Teuscher, C., Threadgill, D.W., Toth, L.A., Toye, A.A., Vadasz, 
C., Van Zant, G., Wakeland, E., Williams, R.W., Zhang, H.G., 
Zou, F. The nature and identification of quantitative trait loci: a 
community´s view. Nat. Rev. Genet. 2003, 4: 911-6. 
[11]  Glazier, A.M., Nadeau, J.H., Aitman, T.J. Finding genes that un-
derlie complex traits. Science 2002, 298: 2345-9. 
[12]  Wakeland, E., Morel, L., Achey, K., Yui, M., Longmate, J. Speed 
congenics: a classic technique in the fast lane (relatively speaking). 
Immunol. Today 1997, 18(10): 472-477. 
[13]  Vingsbo-Lundberg, C., Nordquist, N., Olofsson, P., Sundvall, M., 
Saxne, T., Pettersson, U., Holmdahl, R. Genetic control of arthritis 
onset, severity and chronicity in a model for rheumatoid arthritis in 
rats. Nat. Genet. 1998, 20: 401-404. 
[14]  Olofsson, P., Holmberg, J., Tordsson, J., Lu, S., Åkerstrom, B., 
Holmdahl, R. Positional identification of Ncf1 as a gene that regu-
lates arthritis severity in rats. Nat. Genet. 2003, 33: 25-32. 
[15]  Darvasi, A., Soller, M. Advanced intercross lines, an experimental 
population for fine genetic mapping. Genetics  1995,  141:  1199-
1207. 
[16]  Wang, X., Le Roy, I., Nicodeme, E., Li, R., Wagner, R., Petros, C., 
Churchill, G.A., Harris, S., Darvasi, A., Kirilovsky, J., Roubertoux, 
P.L., Paigen, B. Using advanced intercross lines for high-resolution 
mapping of HDL cholesterol quantitative trait loci. Genome Res. 
2003, 13: 1654-1664. 
[17]  Zhang, S., Lou, Y., Amstein, T.M., Anyango, M., Mohibullah, N., 
Osoti, A., Stancliffe, D., King, R., Iraqi, F., Gershenfeld, H.K. Fine 
mapping of a major locus on chromosome 10 for exploratory and 
fear-like behavior in mice. Mamm. Genome 2005, 16: 306-318. 
[18]  Jagodic, M., Becanovic, K., Sheng, J.R., Wu, X., Backdahl, L., 
Lorentzen, J.C., Wallstrom, E., Olsson, T. An advanced intercross 
line resolves Eae18 into two narrow quantitative trait loci syntenic 
to multiple sclerosis candidate loci. J. Immunol. 2004, 173: 1366-
1373. 
[19]  Sheng, J.R., Jagodic, M., Dahlman, I., Becanovic, K., Nohra, R., 
Marta, M., Iacobaeus, E., Olsson, T., Wallstrom, E. Eae19, a new 
locus on rat chromosome 15 regulating experimental autoimmune 
encephalomyelitis. Genetics 2005, 170: 283-289. 
[20]  Mott, R., Flint, J. Simultaneously detection and fine mapping of 
quantitative trait loci in mice using heterogeneous stocks. Genetics 
2002, 160: 1609-18. 
[21]  DiPetrillo, K., Wang, X., Stylianou, I.M., Paigen, B. Bioinformat-
ics toolbox for narrowing rodent quantitative trait loci. TRENDS in 
Genetics 2005, 21 (12): 683-692. 
[22]  Aitman, T., Glazier, A.M., Wallace, C.A., Cooper, L.D., Norswor-
thy, P.J., Wahid, F.N., Al-Majali, K.M., Trembling, P.M., Mann, 
C.J., Shoulders, C.C., Graf, D., St Lezin, E., Kurtz, T.W., Kren, V., 
Pravenec, M., Ibrahimi, A., Abumrad, N.A., Lawrence, W., 
Stanton, L.W., Scott, J. Identification of Cd36 (Fat) as an insulin-
resistance gene causing defective fatty acid and glucose metabo-
lism in hypertensive rats. Nat. Genet. 1999, 21: 76-83. 
[23]  Karp, C.L., Grupe, A., Schadt, E., Ewart, S.L., Keane-Moore, M., 
Cuomo, P.J., Köhl, J., Wahl, L., Kuperman, D., Germer, S., Aud, 
D., Peltz, G., Wills-Karp, M. Identification of complement factor 5 
as a susceptibility locus for experimental allergic asthma. Nature 
Immunol. 2000, 1(3): 221-226. 
[24]  Rozzo, S.J., Allard, J.D., Choubey, D., Vyse, T.J., Izui, S., Pelts, 
G., Kotzin, B.L. Evidence for an Interferon-inducible gene, Ifi202, 
in the susceptibility of Systemic Lupus. Immunity 2001, 15: 435-
443. 
[25]  Klein, R., Allard, J., Avnur, Z., Nikolcheva, T., Rotstein, D., Car-
los, A.S., Shea, M., Waters, R.V., Belknap, J.K., Peltz, G., Orwoll, 
E.S. Regulation of bone mass in mice by the lipoxygenase gene 
Alox15. Science 2004, 303: 229-232. 
[26]  Wester, L., Olofsson, P., Ibrahim, S., Holmdahl, R. Chronicity of 
pristane-induced arthritis in rats is controlled by genes on chromo-
some 14. J. Autoimmun. 2003, 21(4): 305-13. 
[27]  Wester, L., Koczan, D., Olofsson, P., Holmberg, J., Thiesen, H.J., 
Holmdahl, R., Ibrahim, S. Differential gene expression between the 
pristane-induced arthritis susceptible DA rat and the resistant E3 
rat. Arthritis Res. Ther. 2003, 5(6): R361-72. 
[28]  Otaegui, D., Mostafsvi, S., Bernard, C.C., de Munain, A.L., 
Mousavi, P., Oksenberg, J.R., Baranzini, S.E. Increased transcrip-
tional activity of milk-related genes following the active phase of 
experimental autoimmune encephalomyelitis and multiple sclero-
sis. J. Immun. 2007, 179(6): 4074-82. 
[29]  Bergsteindottir, K., Yang, H.-T., Pettersson, U., Holmdahl, R. 
Evidence for common autoimmune disease genes controlling onset, 
severity, and chronicity based on experimental models for multiple 
sclerosis and rheumatoid arthritis. J. Immunol.  2000,  164: 1564-
1568. 
[30]  Bergin, A.M., Balder, B., Kishore, S., Swärd, K., Hahn-Zoric, M., 
Löwhagen, O., Hanson, L.Å., Padyukov, L. Common variations in 
the IL4R gene affect splicing and influence natural expression of 
the soluble isoform. Human Mutation 2006, 27(10): 990-998. 
[31]  Paleolog E. Angiogenesis in rheumatoid arthritis. Arthritis Res. 
2002, 4(Suppl 3): S81-S90. 
[32]  Binder, R., Kress, A., Kan, G., Herrmann, K., Kirschfink, M. 
Neutrophil priming by cytokines and vitamin D binding protein 
(Gc-globulin): impact on C5a-mediated chemotaxis, degranulation 
and respiratory burst. Mol. Immunol. 1999, 36(13-14): 885-92. 
[33]  Haddad, J.G. Plasma vitamin D-binding protein (Gc-globulin): 
multiple tasks. J. Steroid Biochem. Mol. Biol. 1995, 53(1-6): 579-
82. 
[34]  Yu, X., Bauer, K., Wernhoff, P., Ibrahim, S.M. Using an advanced 
intercross line to identify quantitative trait loci controlling immune 
response during collagen-induced arthritis. Genes Immun.  2007, 
8(4): 296-301. 
[35]  Johannesson, M., Karlsson, J., Wernhoff, P., Nandakumar, K.S., 
Lindqvist, A.K., Olsson, L., Cook, A.D., Andersson, Å., Holmdahl, 
R. Identification of epistasis through a partial advanced intercross 
reveals three arthritis loci within the Cia5 QTL in mice. Genes Im-
mun. 2005, 6(3): 175-85. 
 
 
 